Market capitalization | $21.42m |
Enterprise Value | $20.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.63 |
P/S ratio (TTM) P/S ratio | 0.64 |
P/B ratio (TTM) P/B ratio | 0.38 |
Revenue growth (TTM) Revenue growth | -0.82% |
Revenue (TTM) Revenue | $33.33m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a BioNano Genomics, Inc. forecast:
3 Analysts have issued a BioNano Genomics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 33 33 |
1%
1%
|
|
Gross Profit | -0.60 -0.60 |
107%
107%
|
|
EBITDA | -80 -80 |
40%
40%
|
EBIT (Operating Income) EBIT | -96 -96 |
34%
34%
|
Net Profit | -136 -136 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Robert Holmlin |
Employees | 344 |
Founded | 2003 |
Website | www.bionano.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.